{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:48:14Z","timestamp":1790819294504,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,1,29]],"date-time":"2010-01-29T00:00:00Z","timestamp":1264723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000024","name":"the Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["MCH 97587"],"award-info":[{"award-number":["MCH 97587"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Fonds de la recherche en sant\u00e9 du Quebec"},{"name":"the R\u00e9seau qu\u00e9b\u00e9cois de recherche sur l'usage des m\u00e9dicaments"},{"name":"the R\u00e9seau FRSQ"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purposes<\/jats:title><jats:p>(1) Measure the prevalence and trends of anti\u2010infective drug use before, during, and after pregnancy; (2) to list the doses, classes, types, and indications for anti\u2010infective use during pregnancy; and (3) to identify predictors associated with anti\u2010infective drug use during pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective cohort study within the Quebec Pregnancy Registry, which was created by the linkage of three administrative databases: RAMQ, M\u00e9d\u2010Echo, and ISQ. Women were eligible if they were (1) continuously insured by the RAMQ drug plan for at least 12 months before the first day of gestation, during pregnancy and 12 months after the end of the pregnancy and (2) if they gave birth to a live born between January 1998 and December 2003. Ninety\u2010seven thousand six hundred and eighty pregnant women met the eligibility criteria. Data were collected for systemic agents. Logistic regression models were used to quantify predictors of use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prevalence of anti\u2010infective use during pregnancy was 24.5%. Penicillins use increased compared to other classes. The most frequently diagnosed infections were respiratory and urinary tract infections. Predictors associated with use at the beginning of gestation were having \u22652 different prescribers [OR\u2009=\u20093.83 (95% confidence interval 95%CI: 3.3\u20134.3)], diagnosis of urinary [OR\u2009=\u20091.50 (95%CI: 1.3\u20131.8)], and respiratory tract infection [OR\u2009=\u20091.40 (95%CI: 1.2\u20131.6)] in the year before pregnancy. Visits to an obstetrician\/gynecologist were protective for use [OR\u2009=\u20090.81 (95%CI: 0.67\u20130.97)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anti\u2010infective use during pregnancy is prevalent. The oldest and safest agents are preferred. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1915","type":"journal-article","created":{"date-parts":[[2010,1,29]],"date-time":"2010-01-29T10:52:50Z","timestamp":1264762370000},"page":"418-427","source":"Crossref","is-referenced-by-count":52,"title":["Prevalence and predictors of anti\u2010infective use during pregnancy"],"prefix":"10.1002","volume":"19","author":[{"given":"Fabiano","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Driss","family":"Oraichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anick","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,29]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1225"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8545(05)70326-0"},{"key":"e_1_2_1_4_2","unstructured":"Guidelines.Antimicrobial Therapy \u2013 A Concise Canadian Guide 2007. Montreal: Prism 2007."},{"key":"e_1_2_1_5_2","first-page":"135","article-title":"Antibiotics in pregnancy: are they safe?","volume":"2","author":"Norwitz ER","year":"2009","journal-title":"Rev Obstet Gynecol"},{"key":"e_1_2_1_6_2","first-page":"483","article-title":"Antibiotics and pregnancy","volume":"60","author":"Sa del FF","year":"2005","journal-title":"Pharmazie"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1336"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2008.07.008"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2393-6-18"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0611-6"},{"key":"e_1_2_1_11_2","unstructured":"World Health Organization.International Classification of Diseases.1997."},{"key":"e_1_2_1_12_2","unstructured":"R\u00e9gie de l'assurance maladie du Qu\u00e9bec: Statistiques annuelles. Goverment of Quebec.1997."},{"issue":"2","key":"e_1_2_1_13_2","first-page":"e360","article-title":"Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database","volume":"16","author":"Berard A","year":"2009","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)00234-H"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1558"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117651"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.15.2363"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)03392-8"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.18.1458"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2007.01387.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02837.x"},{"key":"e_1_2_1_22_2","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. WHO Collaborating Centre for Drug Statistics Methodology.http:\/\/www.whocc.no\/atcddd\/(accessed 5 December 2008)."},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(98)00138-9"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050608"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.2000.tb01140.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199705000-00006"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/405868"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(16)32559-2"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1211.060152"},{"key":"e_1_2_1_30_2","article-title":"Prescribing in pregnancy","author":"Wise R","year":"1987","journal-title":"Br Med J"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2006.10.010"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30459-X"},{"key":"e_1_2_1_33_2","unstructured":"Sexually Transmitted Diseases in Canada: 1996 Surveillance Report.Health Canada. Government of Canada 1997."},{"key":"e_1_2_1_34_2","first-page":"e2","article-title":"Drugs in pregnancy: acknowledging challenges \u2013 finding solutions","volume":"14","author":"Koren G","year":"2007","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_1_35_2","first-page":"42","article-title":"Immunology of pregnancy: cellular mechanisms allowing fetal survival within the maternal uterus","volume":"294","author":"Zenclussen AC","year":"2007","journal-title":"Expert Rev Mol Med"},{"key":"e_1_2_1_36_2","first-page":"745","article-title":"Immunology of pregnancy: renewed interest","volume":"22","author":"Le BP","year":"2006","journal-title":"Med. Sci. (Paris)"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1915","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1915","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:22:31Z","timestamp":1696616551000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,29]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1002\/pds.1915"],"URL":"https:\/\/doi.org\/10.1002\/pds.1915","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,29]]}}}